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AMP-activated protein kinase (AMPK) is a key regulator of cellular and systemic energy
homeostasis which achieves this through the phosphorylation of a myriad of downstream
targets. One target is TBC1D1 a Rab-GTPase-activating protein that regulates glucose
uptake in muscle cells by integrating insulin signalling with that promoted by muscle con-
traction. Ser237 in TBC1D1 is a target for phosphorylation by AMPK, an event which may
be important in regulating glucose uptake. Here, we show AMPK heterotrimers containing
the α1, but not the α2, isoform of the catalytic subunit form an unusual and stable asso-
ciation with TBC1D1, but not its paralogue AS160. The interaction between the two pro-
teins is direct, involves a dual interaction mechanism employing both phosphotyrosine-
binding (PTB) domains of TBC1D1 and is increased by two different pharmacological
activators of AMPK (AICAR and A769962). The interaction enhances the efﬁciency by
which AMPK phosphorylates TBC1D1 on its key regulatory site, Ser237. Furthermore, the
interaction is reduced by a naturally occurring R125W mutation in the PTB1 domain of
TBC1D1, previously found to be associated with severe familial obesity in females, with a
concomitant reduction in Ser237 phosphorylation. Our observations provide evidence for
a functional difference between AMPK α-subunits and extend the repertoire of protein
kinases that interact with substrates via stabilisation mechanisms that modify the efﬁcacy
of substrate phosphorylation.
Introduction
AMP-activated protein kinase (AMPK) is a key regulator of cellular and systemic energy homeostasis.
Activation of the enzyme can be brought about by energy stress that is signalled by increases in intra-
cellular AMP:ATP or ADP:ATP ratios, or by increases in intracellular Ca2+ ion concentrations [1,2].
Mammalian AMPK occurs as heterotrimeric complexes comprising α, β and γ subunits, each with
distinct functions. Catalytic activity is conferred by two distinct genes, PRKAA1 and PRKAA2 which
encode the α1 and α2 subunits, respectively [3]. These can form up to 12 different combinations of
αβγ heterotrimer with the β1 and β2 subunits, and the γ1, γ2 and γ3 subunits. Phosphorylation of
threonine 172, in both α1 and α2, is required for maximal activation of AMPK [4]. T172 phosphoryl-
ation can be induced by pharmacological activators of AMPK such as
5-aminoimidazole-4-carboxamide riboside (AICAR), and this is associated with increased glucose
uptake [5–9] and translocation of GLUT4 glucose transporters to the plasma membrane [10] in skel-
etal muscle.
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AMPK-mediated glucose uptake in skeletal muscle is thought to involve TBC1D1 [11,12], a
Rab-GTPase-Activating Protein (Rab-GAP) closely related to AS160 (TBC1D4) [13]. TBC1D1 is highly
expressed in glycolytic muscles [14–16], although recent evidence suggests that TBC1D1 may also play a role in
additional tissues including the pancreas, liver and kidney [17–19]. Both TBC1D1 and AS160 possess two
phosphotyrosine-binding (PTB) domains, a calmodulin-binding domain and a Rab-GAP domain [20]. While
the functions of the TBC1D1 PTB domains are poorly understood, evidence from AS160 [21,22] and TBC1D1
[23] studies suggests regulatory and signalling roles. TBC1D1 is phosphorylated in response to AMPK activa-
tion on multiple sites, with the best characterised being Ser237, within the second PTB domain (PTB2), a cova-
lent modiﬁcation that promotes 14-3-3 protein binding [15,19,24,25].
Sequence variation in TBC1D1 is associated with growth- and obesity-related traits in pigs, chickens and
rabbits [26–29] as well as humans [30,31]. A coding polymorphism (rs35859249; R125W) found in the ﬁrst
PTB domain (PTB1) has been reported in two independent studies to be associated with rare forms of severe
familial obesity in women [20,32]. Our homology model of this domain indicated that R125 is located in a
putative peptide-binding cleft, suggesting a tryptophan substitution would alter protein–protein interactions
[33]. However, how this single-point mutation manifests as a severe obesity phenotype is currently unclear.
The initial aim of the present study was to identify proteins that bind to the PTB domains of TBC1D1 using
Stable Isotope Labelling by Amino acids in Cell culture (SILAC). We found a stable association of AMPK het-
erotrimers containing α1 but not α2 subunits and demonstrate that this has functional consequences for the
kinetics of phosphorylation of the critical AMPK-directed phosphorylation site on TBC1D1, Ser237. We also
demonstrate that this interaction is disrupted by the naturally occurring R125W mutation.
Materials and methods
Antibodies and reagents
Unless otherwise stated all reagents were from Sigma–Aldrich. Primary antibodies against pan-AMPK-α
(#2532), AMPK-β1/2 (#4150), pAMPK Thr172 (#2531), AKT (#4685), ACC (#3876), pACC Ser79 (#3661),
IRAP (#3808), rabbit FLAG (#2368), Raptor (#2280), pRaptor Ser792 (#2083) and TBC1D1 (#5929) were from
Cell Signaling Technology. Other antibodies were pan-14-3-3 (sc-629) and GST (sc-138) from Santa Cruz
Biotechnology Inc., GFP (118144600001; Roche), AMPK-γ1 (ab32508; Abcam), pTBC1D1 Ser237 (#07-2268;
Merck-Millipore), β-actin (A1978) and mouse FLAG (F1804). Isoform-speciﬁc AMPK-α antibodies were
described previously [34]. A769662 (Abcam) and AICAR (Tocris) were used.
Mouse model
Transgenic MCK-3xFLAG-Tbc1d1 mice with muscle-speciﬁc overexpression of Tbc1d1 were generated by
cloning of PCR-ampliﬁed 3xFLAG-Tbc1d1 from skeletal muscle cDNA into pBSK-MCK containing exon, one
of the muscle creatine kinase promoters. The construct was injected into the fertilised oocytes of FVB/N inbred
mice (Prof. Fatima Bosch and Dr. Anna Pujol, UAT-CBATEG, Barcelona, Spain). A founder line with high
(5-fold) Tbc1d1 overexpression in heart and skeletal muscle tissue was backcrossed to the N7 generation with
C57BL/6J mice using marker-assisted genotyping.
Mice were kept in accordance with the National Institutes of Health guidelines for the care and use of
laboratory animals, and all experiments were approved by the Ethics Committee of the State Ministry of
Agriculture, Nutrition and Forestry (State of North Rhine-Westphalia, Germany). Three to six mice per cage
(Macrolon type III) were housed at a temperature of 22°C and a 12-h light–dark cycle (lights on at 6 a.m.) with
ad libitum access to food and water. After weaning, animals received a standard chow diet (V153 3 R/M-H;
Ssniff, Soest, Germany). Male mice between 10 and 14 weeks were killed by cervical dislocation, quadricep
muscle was dissected and directly snap-frozen in liquid nitrogen.
Molecular biology
TBC1D1 constructs and AS160 were cloned from pCMV5.HA-1 TBC1D1 and p3xFLAG-CMV-10 AS160
(kind gifts respectively from Kei Sakamoto, Nestlé Institute of Health Sciences S.A., Switzerland [25] and Gus
Lienhard, Dartmouth Medical School, US) respectively, into pXLG3 for lentiviral expression or pEGFP-C1 for
transient expression to yield constructs with an N-terminal GFP tag. Secondary structure prediction, described
previously [33], determined PTB domain regions as residues 1-161 (PTB1), 162–381 (PTB2) and 1–381 (PTB1
+ 2). QuikChange site-directed mutagenesis (Agilent Technologies) introduced point mutations, TCC to GCC
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(S237A), ATG to CTG (M232L), ATG to GCG (M232A), CGC to GCC (R233A), CTG to GCG (L241A), CGG
to TGG (R125W) into TBC1D1 and AAG to AGG (L47R — kinase-dead mutation) into AMPKα1. The PTB1
+ 2 domain of TBC1D1, wild-type and R125W mutant, was cloned into pGEX-6P-3 with a C-terminal
Hexa-His-tag and a C-terminal Hexa-His-tag was cloned onto GST in pGEX-6P-3.
Cell culture and generation of stable cell lines
C2C12 (American Type Culture Collection), Flp-In HEK293 (Invitrogen) and HEK293T cell lines were cul-
tured in DMEM supplemented with 10% (v/v) FBS (Invitrogen), 50 IU/ml penicillin, 50 mg/ml streptomycin
and 2 mM glutamine. C2C12 cells were differentiated into myotubes as previously described [35]. HEK293T
cells were used to produce lentiviral particles which were added to C2C12 myoblasts to generate stably trans-
duced cell lines. Flp-In HEK293 cell lines stably expressing either FLAG-tagged AMPK-α1 or -α2 were previ-
ously described [36].
Generation of AMPK-α1/-α2 double knockout (DKO) HEK293 Flp-In cells
Knockout of AMPK-α1 and -α2 (PRKAA1 and PRKAA2) in HEK293 Flp-In cells was performed via the
CRISPR-Cas9 method [37] using the targeting oligos, methodology and validation as described previously [38].
As some residual activity was initially detected by enzyme assay at very low levels, probably due to the poly-
ploid nature of the HEK cell line, the process was repeated on these cell lines to remove all detectable AMPK
activity.
After transfection with FuGENE 6 (Promega), α1/α2 DKO cells expressing either FLAG-AMPK-α1 or
FLAG-AMPK-α1 K47R were selected and single foci expanded in complete medium supplemented with blasti-
cidin (15 mg/ml) and hygromycin B (200 mg/ml).
SILAC interactome analysis
Transduced C2C12 myoblasts were expanded in R0K0 or R6K4 isotopically labelled DMEM (Dundee Cell
Products) for at least six passages prior to differentiation. Myotubes were harvested in precipitation buffer
(50 mM Tris–HCl pH 7.4, 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 0.5% NP40, 1 mM DTT,
50 mM NaF, 5 mM Na4P2O7, 1 mM Na3VO4, 0.5 mM PMSF, Calbiochem protease inhibitor cocktail), lysates
incubated (4°C, 1 h) with GFP-trap beads (ChromoTek), precipitates washed four times with precipitation
buffer and samples pooled prior to eluting, SDS–PAGE and Nano LC–MS/MS on an Orbitrap Velos (Thermo
Fisher Scientiﬁc). Mass spectrometric detection and quantiﬁcation was performed as previously published [39].
Shown is a subset of the interacting proteins identiﬁed.
Immunoprecipitation and western blot analysis
Transduced C2C12 myotubes or Flp-In HEK293 cells transfected by polyethylenimine with GFP constructs for
48 h were harvested in precipitation buffer and GFP-trap performed as described above. For mouse muscle
immunoprecipitations, anti-FLAG antibody was preconjugated to protein-G-coated agarose beads which were
subsequently blocked in precipitation buffer containing 1% BSA and then incubated overnight at 4°C with
homogenised quadriceps muscle (4 mg) or precipitation buffer and subsequently washed. For endogenous
reciprocal immunoprecipitations, AMPK-α1 antibody or sheep IgG was preconjugated to protein-G-coated
sepharose beads which were then incubated (4°C, 2 h) with lysates from C2C12 myotubes harvested in precipi-
tation buffer and subsequently washed. Standard western blot procedures were performed. Signal was detected
by either a LI-COR Odyssey infrared imaging system of ﬂuorescently labelled secondary antibodies or ECL of
HRP-conjugated secondary antibodies.
Protein expression and recombinant interaction studies
Glutathione S-transferase (GST)-tagged or dual GST/His-tagged proteins were expressed upon IPTG induction
in Escherichia coli BL21 (DE3) overnight at 15°C, puriﬁed using talon afﬁnity resin (Clontech), eluted with
200 mM imidazole, 50 mM Tris–HCl (pH 8), 300 mM NaCl, 5 mM 2-mercaptoethanol, 5% glycerol and subse-
quently immobilised and puriﬁed on glutathione sepharose (GE Healthcare). For pull-down experiments,
immobilised puriﬁed proteins (2 or 4 mg) were incubated (4°C, 30 min or 1 h) with Flp-In HEK293 cell lysate
(5 mg) in precipitation buffer supplemented with 2 mM ATP and 5 mM MgCl2. Additional A769662 (25 mM)
or vehicle was spiked into activation experiment pull-downs during the 4°C incubation step. After extensive
washing bound proteins were detected via western blotting. Recombinant AMPK trimer complexes were
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expressed in E. coli and puriﬁed as previously published [40]. For direct interaction pull-down experiments,
immobilised puriﬁed GST-PTB1 + 2 (2 mg) was incubated (4°C, 1 h) with the puriﬁed AMPK trimer complexes
(1 mg) in supplemented precipitation buffer without EDTA and EGTA and handled as described above.
Signalling experiments
Cells transfected for 48 h were treated as speciﬁed in ﬁgure legends and harvested in ice-cold lysis buffer
(50 mM HEPES pH 7.4, 150 mM NaCl, 1% Triton-X-100, 1 mM Na3VO4, 30 mM NaF, 10 mM Na4P2O7,
10 mM EDTA, 0.5 mM PMSF, Calbiochem protease inhibitor cocktail). To reduce basal AMPK, cells were pre-
treated with STO-609 (25 mM, 30 min) as previously described [41,42]. Protein content was determined by
BCA assay (Thermo Fisher Scientiﬁc) and equal amounts were analysed.
Statistics
GraphPad Prism 7.0 software was used for statistical analyses as indicated in the ﬁgure legends.
Results
AMPK, but not Akt, stably associates with TBC1D1
In exploring the role of the PTB domains of TBC1D1, we used SILAC-based quantitative proteomics to identify
proteins that interact with a GFP-tagged construct comprising the two tandem N-terminal PTB1-PTB2
domains (GFP-PTB1 + 2; Figure 1A). Immunoprecipitation via GFP-Trap from C2C12 myotubes stably expres-
sing the GFP-PTB1 + 2 construct revealed several proteins to be 5- to 100-fold enriched in the GFP-PTB1 + 2
precipitates compared with the control (Figure 1B). This included protein families known to interact with the
PTB domains of TBC1D1: IRAP (insulin-responsive aminopeptidase) and several isoforms of 14-3-3 proteins
(the α/β, γ, ε, ζ/δ and η; Figure 1B) [15,21,24,25]. We also observed an 11.6-fold enrichment of the α1 subunit
of AMPK, together with substantial enrichments of the β1, β2 and γ1 subunits (Figure 1B). This was validated
by western blotting with a pan-α subunit antibody (Figure 1C). We additionally conﬁrmed that the α, β and γ
subunits of AMPK bound to full-length GFP-tagged TBC1D1 expressed in C2C12 myotubes (Figure 1D) and
to a FLAG-tagged TBC1D1 transgene expressed in mouse quadriceps muscles (Figure 1E). These results indi-
cate that AMPK heterotrimers bind to the TBC1D1 PTB domains with an afﬁnity that is sufﬁciently high to
survive immunoprecipitation and extensive washing.
Consistent with its absence in the SILAC data, we saw no evidence for a stable interaction of the Akt protein
kinase with TBC1D1 expressed in either C2C12 myotubes or mouse quadriceps (Figure 1D,E). Given that both
AMPK and Akt phosphorylate TBC1D1, albeit on different sites, our data suggest that the interaction of
AMPK with TBC1D1 is not a general kinase-substrate-related phenomenon.
TBC1D1 PTB domains directly and preferentially bind to AMPK complexes
containing α1-subunits relative to α2-subunits
Interestingly, our SILAC data revealed an enrichment of AMPK-α1 peptides in the TBC1D1 precipitates, but
not of AMPK-α2 peptides (Figure 1B). Using isoform-speciﬁc AMPK-α antibodies [34], we conﬁrmed that the
interaction of TBC1D1 was indeed speciﬁc to AMPK complexes containing the α1 and not α2 subunit
(Figure 2A).
To corroborate the selectivity in AMPK-α subunit binding, we incubated puriﬁed immobilised GST-PTB1 +
2 protein with lysates of Flp-In HEK293 cells stably expressing either FLAG-tagged AMPK-α1 or FLAG-tagged
AMPK-α2 subunits [36]. Consistent with our previous results, GST-PTB1 + 2 interacted with FLAG-AMPK-α1
to a greater extent than with FLAG-AMPK-α2 (Figure 2B,C). Interestingly, phosphorylation of GST-PTB1 + 2
at Ser237, which occurred during the incubation of the recombinant protein with the lysate, was signiﬁcantly
higher in the presence of FLAG-AMPK-α1 relative to FLAG-AMPK-α2 and accordingly resulted in enhanced
14-3-3 protein pull-down (Figure 2B,C). Moreover, we performed the reciprocal immunoprecipitation to
further conﬁrm the interaction between FLAG-tagged AMPK-α1 and TBC1D1 (Supplementary Figure S1).
To assess whether the AMPK–TBC1D1 interaction was direct or indirect via another intermediary protein,
such as 14-3-3, the puriﬁed immobilised GST-PTB1 + 2 protein was incubated with four different recombinant
AMPK heterotrimer complexes puriﬁed from E. coli. Consistent with a direct interaction, AMPK heterotrimers
comprising α1 subunits (namely α1β1γ1 and α1β2γ1) bound robustly, whereas those containing α2 subunits
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(α2β1γ1 and α2β2γ1) associated only weakly (Figure 2D,E). Taken together, the data indicate that AMPK het-
erotrimers comprising α1 but not α2 subunits bind directly to the PTB domains of TBC1D1.
AMPK activation enhances the binding of AMPK-α1 to TBC1D1
Next, we examined whether activation of AMPK regulates the interaction with TBC1D1. GFP-trap precipitates
from C2C12 myotubes treated with the AMPK activator, AICAR, were analysed. As shown in Figure 3A,B,
AICAR stimulated an ∼4-fold increase in the binding of TBC1D1 with AMPK complexes containing
Figure 1. AMPK precipitates with TBC1D1 PTB domains in C2C12 myotubes.
(A) Schematic of the SILAC experiment set-up used to identify proteins interacting with the PTB domains of TBC1D1 in
differentiated C2C12 myotubes. (B) Table of a subset of the proteomics output. Score: combines several parameters (a high
score generally signiﬁes a high protein abundance and a high conﬁdence in the detection and quantiﬁcation by the software).
Enrichment: Ratio of the quantiﬁcation values of the medium (GFP-PTB 1 + 2) and light (GFP) quantiﬁcation channels.
Coverage: percentage of the protein sequence covered by identiﬁed peptides. # PSMs (peptide spectrum matches): total
number of identiﬁed peptide sequences (includes those redundantly identiﬁed). # Peptides: total number of unique identiﬁed
peptides. (C) Western blot validation of proteomics results. GFP-trap precipitates from C2C12 myotube extracts, lentivirally
transduced to express either GFP or GFP-PTB1 + 2 blotted for the proteins indicated. (D) Lysates from differentiated C2C12
myotubes lentivirally transduced with GFP or full-length GFP-tagged TBC1D1 (GFP-TBC1D1) subjected to GFP-trap and
western blotting for the proteins indicated. (E) Homogenised quadricep lysates from either wild-type (WT) mice or mice
expressing 3xFLAG-TBC1D1 were immunoprecipitated with a FLAG antibody and resulting complexes analysed.
Representative blots of n = 4 independent experiments.
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α1-subunits. This occurred together with parallel increases in TBC1D1 phosphorylation on Ser237 and 14-3-3
binding. The α2 subunit was not detected in precipitates (Figure 3A) despite pharmacological activation of
AMPK that resulted in enhanced AMPK and ACC phosphorylation (Figure 3C). Likewise,
co-immunoprecipitation of endogenous TBC1D1 with endogenous AMPK-α1 was increased upon AICAR
stimulation in the C2C12 myotubes (Supplementary Figure S2).
A recent quantitative proteomic analysis reported signiﬁcantly higher expression of the α1 subunit compared
with α2 in C2C12 cells [43]. We thus sought to address whether the apparent lack of association with AMPK
Figure 2. TBC1D1 binds AMPK-α1 and not AMPK-α2 heterotrimeric complexes.
(A) Lysates from differentiated C2C12 myotubes lentivirally transduced with GFP or GFP-TBC1D1 subjected to GFP-trap and
western blotting for AMPK-α isoforms. (B) Immobilised GST-His or GST-PTB1 + 2-His proteins were incubated with lysis buffer
only (-) or lysates from Flp-In HEK293 cells stably expressing either FLAG-tagged AMPK-α1 or AMPK-α2. Washed complexes
were analysed by western blotting. (C) Quantitation of data in (B), normalised to GST-PTB1 + 2-His and expressed in terms of
FLAG-AMPK-α1 pull-down. Mean ± SEM; ﬁve independent experiments; two-tailed t-test *P < 0.05, **P < 0.01, ****P < 0.0001.
(D) Immobilised GST or GST-PTB1 + 2 proteins were incubated with lysis buffer only (-) or puriﬁed recombinant AMPK αβγ
heterotrimeric complexes as indicated and washed pull-downs analysed. Representative blots of four independent
experiments. (E) Quantitation of data in (D), normalised to GST-PTB1 + 2. Mean ± SEM; four independent experiments; one-way
ANOVA Dunnett’s post-test *P < 0.05 ****P < 0.0001 cf pull-down of α1β1γ1.
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).2974
Biochemical Journal (2018) 475 2969–2983
https://doi.org/10.1042/BCJ20180475
α2-subunits in the presence of an AMPK activator was not simply due to low endogenous α2 expression levels
in these cells. To do this, we turned to the Flp-In HEK293 cell system which stably express equal levels of
FLAG-AMPK-α1 or FLAG-AMPK-α2, largely replacing endogenous AMPK-α [36], and used the allosteric
AMPK activator, A769662 (Figure 3D,E). Consistent with our previous results, A769662 promoted an increase
in the binding of FLAG-AMPK-α1 but not of FLAG-AMPK-α2 to TBC1D1 PTB domains (Figure 3D,E) under
Figure 3. AMPK activation increases the association of AMPK-α1 with TBC1D1.
(A) Western blot analysis of GFP-trap precipitates from differentiated C2C12 myotubes lentivirally transduced with GFP or
GFP-TBC1D1, serum starved for 4–5 h, prior to the addition of vehicle or AICAR (2 mM) for the times indicated. (B) Quantitation
of data shown in (A) normalised to GFP-TBC1D1 precipitated and presented as fold over basal pull-down. Mean ± SEM; three
to four independent experiments; one-way ANOVA Dunnett’s post-test *P < 0.05, **P < 0.01 cf Basal. (C) Total cell lysates (TCL)
from (A) analysed for total and phosphorylated proteins. (D) Immobilised GST-His or GST-PTB1 + 2-His proteins were
incubated with lysis buffer only (-) or lysates from Flp-In HEK293 cells stably expressing FLAG-AMPK-α1 or FLAG-AMPK-α2.
Cells had been serum starved (4–5 h) prior to the addition of STO-609 (25 mM, 30 min) and subsequent treatment with either
vehicle or A769662 (25 mM, 30 min). Washed complexes were analysed by western blotting. (E) Quantitation of data in
(D), AMPK-α1 (black) and AMPK-α2 (white), normalised to GST-PTB1 + 2-His and expressed in terms of FLAG-tagged
AMPK-α1 pull-down (black). Mean ± SEM; four to seven independent experiments; two-way ANOVA Bonferroni post-test
** P < 0.01. (F) Total cell lysates (TCL) from (D) analysed for total and phosphorylated proteins.
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conditions where AMPK was clearly activated as demonstrated by increases in AMPK, ACC and Raptor phos-
phorylation (Figure 3F).
The AMPK–TBC1D1 interaction requires the TBC1D1 PTB2 domain is
enhanced by the presence of the PTB1 domain and inhibited by a R125W
mutation in PTB1
Our studies in the C2C12 myotube system revealed that AMPK-α subunits bound to the PTB2 domain,
which contains the critical AMPK-directed Ser237phosphorylation site, but not to the PTB1 domain alone
(Figure 4A,B). Interestingly, however, we consistently found that the presence of PTB1 enhanced the inter-
action as demonstrated by the greater pull-down with GFP-PTB1 + 2 and GFP-TBC1D1 compared with
GFP-PTB2 (Figure 4B). This suggests there is co-operativity between the PTB1 and PTB2 domains in conferring
optimal AMPK binding.
To explore the contribution of the enzyme/peptide substrate interaction interface (or ‘catalytic interface’) in
facilitating the AMPK–TBC1D1 interaction, we mutated the AMPK-mediated phosphorylation site Ser237 to an
alanine in the context of both PTB1 + 2 and PTB2 constructs (Figure 4C,D). Mutation of Ser237 abolished
AMPK binding to a GFP-tagged PTB2 domain, suggesting the interaction of this domain with AMPK is
dependent on the presence of a phosphorylatable residue. In contrast, however, the S237A mutation only par-
tially (42%) inhibited AMPK binding to GFP-PTB1 + 2 (Figure 4C,D). Very similar results were obtained if we
mutated Met232, Arg233 and Leu241 which are key consensus sequence residues surrounding Ser237 [44]
(Supplementary Figure S3A,B). Importantly, while the S237A, M232A, R233A and L241A mutant forms of full-
length TBC1D1 retained AMPK binding similar to the wild-type in the absence of A769662, the kinase was
unable to phosphorylate Ser237 (Supplementary Figure S3B). We additionally found that the kinase activity of
α1 was not required for TBC1D1 binding as, surprisingly, a kinase-dead mutant expressed in a CRISPR/Cas9
HEK293 α1/α2 double knockout (HEK293-DKO) cell line (Supplementary Figure S4A,B) showed enhanced
binding to GST-PTB1 + 2 (Supplementary Figure S4C,D).
Taken together, these data suggest that the catalytic interface encompassing the Ser237 phosphorylation site is
just one element of the mechanism involved in mediating the stable AMPK–TBC1D1 interaction, and that
PTB1 plays an important synergistic role, perhaps by providing a second interaction interface with AMPK-α1.
Given the cooperation of the PTB1 domain with PTB2 in promoting the AMPKα1–TBC1D1 interaction, we
considered whether the naturally occurring R125W mutation within the PTB1 domain, associated with a rare
form of severe obesity, alters the interaction. The R125W mutation signiﬁcantly reduced the association of
AMPK with TBC1D1 in C2C12 myotubes (Figure 4E), an observation that was corroborated by reduced
FLAG-AMPK-α1 pull-down, from Flp-in HEK293 cells, with GST-PTB1 + 2 R125W compared with the wild-
type protein (Figure 4F). These data further implicate PTB1 in playing an important role in modifying the
AMPK–TBC1D1 interaction.
AMPK binds TBC1D1 but not AS160
We also investigated whether the ability of TBC1D1 to bind AMPK was shared by the paralogue AS160, which
is highly expressed in adipose tissue but also found in both type I and II muscle ﬁbres [45,46] with mouse
glycolytic muscle previously shown to express a relatively lower level of AS160 [14]. TBC1D1 and AS160
possess similar domain structures (Figure 4A), exhibiting 37 and 43% sequence identity within their PTB1 and
PTB2 domains, respectively [13]. Like TBC1D1, AS160 can be phosphorylated by AMPK on Ser341 within the
PTB2 domain and on Ser704 [47,48]. However, unlike TBC1D1, AS160 did not appear to bind to AMPK in
C2C12 myotubes under conditions where 14-3-3 proteins bound to both TBC1D1 and AS160 (Figure 4B).
The stable association of AMPK promotes enhanced TBC1D1 Ser237
phosphorylation
To investigate whether the stable association of TBC1D1 with AMPK changes the kinetics of TBC1D1 phos-
phorylation at Ser237, we transiently expressed GFP-TBC1D1 in Flp-In HEK293 cells stably expressing
FLAG-AMPK-α1 or FLAG-AMPK-α2. To reduce basal AMPK activation, cells were pre-treated with the Ca2
+/calmodulin-dependent protein kinase kinase 2 inhibitor STO-609 as previously described [41,42]. As shown
in Figure 5A,B, activation of AMPK with A769662 resulted in increased TBC1D1 Ser237 phosphorylation in
both cell lines over the course of 45 min. However, cells expressing FLAG-AMPK-α1 subunits showed a
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).2976
Biochemical Journal (2018) 475 2969–2983
https://doi.org/10.1042/BCJ20180475
signiﬁcantly higher fold increase in TBC1D1 Ser237 phosphorylation than cells expressing FLAG-AMPKα2.
This difference was speciﬁc to TBC1D1, since the phosphorylation of another substrate, ACC, as well as of
AMPK on T172, was very similar in cells expressing FLAG-AMPK-α1 or FLAG-AMPK-α2 (Figure 5A,C).
Taken together, this suggests that the stable association of AMPK-α1 with TBC1D1 which enhances the efﬁcacy
by which Ser237 is phosphorylated by AMPK.
Figure 4. The AMPK–TBC1D1 interaction requires the TBC1D1 PTB2 domain is enhanced by the presence of the PTB1
domain and reduced by a R125W mutation in PTB1.
(A) Schematic overview of the GFP-tagged constructs used in pull-down experiment in (B). (B) Lysates from differentiated
C2C12 myotubes lentivirally transduced with GFP-tagged constructs as indicated were subjected to GFP-trap and western
blotting for the proteins indicated. (C) Analysis of GFP-trap precipitates from differentiated C2C12 myotubes lentivirally
transduced with indicated GFP-tagged constructs. (D) Quantitation of AMPK-α precipitation, shown in (C), normalised to
GFP-tagged protein precipitated and expressed in terms of GFP-PTB1 + 2 pull-down. Mean ± SEM; three independent
experiments; one-way ANOVA Dunnett’s post-test **P < 0.01, ****P < 0.0001 cf GFP-PTB1 + 2. (E) Lysates from differentiated
C2C12 myotubes lentivirally transduced with GFP-TBC1D1 or GFP-TBC1D1 R125W were subjected to GFP-trap and western
blotting. Shown is the quantitation of AMPK-α subunit precipitated with wild-type or mutant protein normalised to GFP-tagged
protein precipitated. Mean ± SEM; 12 independent experiments; two-tailed t-test *P < 0.05. (F) Immobilised recombinant
puriﬁed GST-PTB1 + 2-His or GST-PTB1 + 2 R125W-His proteins were incubated with lysates from Flp-In HEK293 cells stably
expressing FLAG-tagged AMPK-α1. Washed complexes were analysed by western blotting. Shown is the quantitation of
FLAG-AMPK-α1 precipitated with wild-type or mutant protein normalised to GST-tagged protein content. Mean ± SEM; four
independent experiments; two-tailed t-test **P < 0.01.
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The reduction in the AMPK–TBC1D1 interaction brought about by the R125W mutation would be pre-
dicted, based on our previous results (Figure 4E,F), to reduce TBC1D1 Ser237 phosphorylation. To explore this,
Figure 5. Cells expressing AMPK-α1 facilitate enhanced Ser237 phosphorylation of TBC1D1 which is reduced by the
naturally occurring R125W mutation.
(A) Analysis of phosphorylation of transiently expressed GFP-TBC1D1 as well as AMPK and ACC and total proteins from Flp-In
HEK293 cells stably expressing FLAG-AMPK-α1 or FLAG-AMPK-α2. Cells had been serum starved (4–5 h) prior to the addition
of STO-609 (25 mM, 30 min) and subsequent treatment with either vehicle or A769662 (25 mM) for the times indicated. (B and
C) Quantitation of ﬂuorescence-based Western blot data shown in (A) in FLAG-AMPK-α1 (black squares) and FLAG-AMPK-α2
(white triangles) expressing cells; Ser237 phosphorylation normalised to GFP-tagged protein expression; AMPK phosphorylation
normalised to FLAG-AMPK-α1 or FLAG-AMPK-α2 expression; ACC phosphorylation normalised to total ACC expression. All
displayed as a fold over basal phosphorylation. Mean ± SEM; six independent experiments; two-way ANOVA Bonferroni
post-test **P < 0.01. (D) Quantitative ﬂuorescence-based Western blot analysis of phosphorylation of TBC1D1, AMPK and ACC
and total proteins from CRISPR/Cas9 α1/α2 double knockout (DKO) HEK293 stably expressing FLAG-AMPK-α1 and transiently
expressing either GFP-TBC1D1 or GFP-TBC1D1 R125W. Cells had been serum starved (4–5 h) prior to the addition of
STO-609 (25 mM, 30 min) and subsequent treatment with either vehicle or A769662 (25 mM) for the times indicated. (E and F)
Quantitation of data shown in (C) in GFP-TBC1D1 (black circles) and GFP-TBC1D1 R125W (white diamonds) expressing cells;
Ser237 phosphorylation normalised to GFP-tagged protein expression; AMPK phosphorylation normalised to FLAG-AMPK-α1
expression; ACC phosphorylation normalised to total ACC expression. All displayed as a fold over basal phosphorylation.
Mean ± SEM; ﬁve independent experiments; two-way ANOVA Bonferroni post-test *P < 0.05.
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we used the CRISPR/Cas9 HEK293-DKO cell line that stably expressed FLAG-AMPK-α1 (Supplementary
Figure S4). A GFP-TBC1D1 R125W mutant transiently expressed in these cells did indeed exhibit reduced
phosphorylation of Ser237 compared with the wild-type protein (Figure 5D,E). This was not due to a difference
in cellular AMPK activity in the R125W expressing cells, as the kinetics of AMPK and ACC phosphorylation
were the same in both cell lines (Figure 5D,F). Moreover, this was speciﬁc to cells expressing FLAG-AMPK-α1
as no difference in Ser237phosphorylation was observed in FLAG-AMPK-α2 expressing cells (Supplementary
Figure S5).
Discussion
Our ﬁndings demonstrate that AMPK heterotrimers containing α1 but not α2 subunits form a direct stable
association with TBC1D1, but not with its paralogue AS160, which enhances the efﬁcacy of phosphorylation of
a TBC1D1 on Ser237, a key regulatory site. To the best of our knowledge, our results provide the ﬁrst evidence
for a substantive difference in substrate selection between the α1 and α2 subunits of AMPK in vitro or in intact
cells; previous studies have revealed only very subtle differences [34]. The difference we observe is especially
striking given the 76% sequence similarity between α1 and α2 subunits, which reaches 90% within the catalytic
domains.
Typically, protein kinases do not bind substrates with sufﬁciently high afﬁnity for their interaction to survive
cell lysis, immunoprecipitation and extensive washing of the complexes. Based on our results, therefore, we
propose a dual interaction mechanism for the stable interaction of AMPK α1-containing heterotrimers with
TBC1D1.
One of these interaction mechanisms appears to involve the catalytic interface encompassing the substrate-
binding cleft of the AMPK-α1 subunit and its target Ser237 phosphorylation site within the PTB2 domain.
Evidence for this derives from the fact that the interaction: (i) is reduced by mutation of Ser237 and its neigh-
bouring residues, Met232, Arg233 and Leu241, that together confer selective substrate binding by AMPK
(Figure 4D and Supplementary Figure S3); and (ii) is enhanced by pharmacological AMPK activators
(Figure 3). Furthermore, a kinase-inactive mutant of the AMPK-α1 subunit exhibits enhanced binding to
TBC1D1 (Supplementary Figure S4), suggesting that the process of Ser237 phosphorylation may ultimately be
required to release AMPK from TBC1D1.
We propose that a second interaction interface exists outside the substrate-binding cleft. Evidence for this
derives from three observations: (i) that the presence of PTB1 substantially enhances the binding of the PTB2
domain to AMPK (Figure 4); (ii) that an R125W mutation in the PTB1 domain signiﬁcantly reduces binding
of TBC1D1 to AMPK (Figure 4E,F); and (iii) that disruption of the catalytic interface within PTB2 brought
about by mutating Met232, Arg233, Ser237 or Leu241 only partially reduces the interaction between AMPK and
TBC1D1 in the context of full-length TBC1D1 containing both PTB1 and PTB2 domains (Figure 4D and
Supplementary Figure S3). These data suggest that the secondary binding interface could lie within the PTB1
domain, although if this is the case, the binding afﬁnity is insufﬁcient for the PTB1 domain to co-precipitate
with AMPK when it is expressed in isolation (Figure 4B). Alternatively, the secondary binding interface could
lie within the PTB2 domain and its afﬁnity for AMPK-α1 subunits might be allosterically regulated by the pres-
ence of PTB1 or by the R125W mutation in the PTB1 domain. We cannot exclude a third possibility where
regions within both the PTB1 and PTB2 domains contribute to the secondary binding interface.
Docking sites, external to protein kinase catalytic interfaces, are well established to facilitate alignment of the
substrate phospho-acceptor site with its cognate protein kinase substrate-binding groove to enhance phosphor-
ylation efﬁciency (reviewed in [49–51]). The best-characterised examples of this include a MAP kinase docking
site which can drive both positive and negative substrate selections, and PDK1 which possesses a hydrophobic
pocket that interacts with a hydrophobic motif present on all its substrates [49]. Formal identiﬁcation of the
mode of binding between AMPK and TBC1D1 will require structural studies of the puriﬁed complex.
It is well established that muscle contraction stimulates AMPK activity and increases TBC1D1 Ser237 phos-
phorylation and that this is associated with an increase in muscle glucose uptake [52]. Our data support a role
for the stable interaction between AMPK-α1 heterotrimers and TBC1D1 in enhancing TBC1D1 Ser237 phos-
phorylation. This is substantiated by our observations that TBC1D1 Ser237 phosphorylation is: (i) enhanced in
cells expressing α1 subunit-containing AMPK heterotrimers versus those expressing α2-containing heterotri-
mers (under conditions where phosphorylation of ACC on Ser79 was no different between AMPK-α1 and
AMPK-α2 heterotrimeric expressing cells; Figure 5); and (ii) is reduced in cells expressing the R125W mutant
TBC1D1 versus those expressing the wild-type protein (Figure 5). The observed alteration in phosphorylation
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of Ser237 could have important downstream signalling consequences. For example, while insulin does not regu-
late TBC1D1 Ser237 phosphorylation, our data could explain the previously reported ability of the R125W
mutation in TBC1D1 to prevent insulin-stimulated trafﬁcking of GLUT4 to the plasma membrane, following a
prerequisite AICAR pre-stimulation, when exogenously expressed in pre-adipocytes [23] as well as inhibiting
insulin-stimulated, but interestingly not electrically induced contraction-stimulated, glucose transport when
overexpressed in mouse skeletal muscle [53]. These observations could be related to inhibition of insulin-
stimulated glucose uptake by the binding of APPL2 to TBC1D1 at an adjacent insulin-stimulated Ser235 phos-
phorylation site [54]. Given the proximity of this binding site to Ser237, the association of TBC1D1 and APPL2
may be affected by the physical presence of AMPK and thus it is conceivable that reduced AMPK binding to
TBC1D1 R125W may facilitate APPL2-mediated inhibition of insulin-stimulated glucose transport.
Unfortunately, we have not been able to test this hypothesis because we have been unable to detect the binding
of APPL2 to TBC1D1 in C2C12 myotubes.
The roles of α1- and α2-containing AMPK heterotrimers in tissues are the subject of much debate in the
literature. AMPK complexes containing α2, but not α1, subunits are reported to be activated by contraction
[55–59] and that contraction-induced phosphorylation of Ser237 phosphorylation is impaired in α2, but not α1,
knockout mice [24]. In mouse models where AMPK-α2 is either inactivated or knocked-out in skeletal muscle,
contraction-stimulated glucose uptake remains normal [6,7,60] or only partially reduced [5,8], whereas it is
substantially impaired in β1/β2 knockout muscles, where all AMPK kinase activity is completely lost [61].
The latter being congruent with other groups who have suggested that AMPK-α1 and AMPK-α2 heterotrimeric
complexes respond to speciﬁc types and durations of contraction making the picture much more complicated
[62–68].
AMPK has been proposed as an attractive drug target for the treatment of metabolic diseases which has led
to great interest in the development of isoform selective compounds [69], such the allosteric activator of
α1-containing heterotrimeric complexes C2 [70]. While the differential roles of the catalytic α-subunit are cur-
rently limited [3] distinctions between the catalytic subunits, such as the association of α1 subunit-containing
AMPK heterotrimers with TBC1D1, may enable selective modiﬁcation of AMPK function.
The binding of α1-containing complexes to TBC1D1 may have important roles in non-muscle cell types
where α1 subunit expression and activity predominates over α2. In human hepatocytes, for example, expression
of α1β2γ1 heterotrimers predominates [71], and in these cells metformin stimulates Ser237 phosphorylation on
TBC1D1 via AMPK activation [19]. Interestingly, in mouse hepatocytes TBC1D1 localises to insulin-like
growth factor 1 (IGF1)-containing storage vesicles, and a TBC1D1 S231A (equivalent to Ser237 in humans)
knock-in mutation promotes increased IGF1 secretion from the liver, leading to lipogenic gene expression in
adipose tissue and consequent obesity [19]. Taken together with our data, this could suggest that in hepatocytes
the α1β2γ1heterotrimer stably bound to TBC1D1 plays an important role in metformin-induced suppression
of IGF1 secretion, a phenomenon that is reduced in the S231A knock-in mouse. Moreover, given the (i)
reduced Ser237 phosphorylation of the R125W mutant demonstrated in our experiments and (ii) IGF1
hypersecretion-mediated obesity in the knock-in mouse where Ser231 can no longer be phosphorylated; an
attractive hypothesis is that the observed severe obesity phenotype in a subset of women with the R125W
mutation may occur via a mechanism involving elevated circulating levels of IGF1. In summary, we have
shown that α1-containing AMPK heterotrimers bind stably to TBC1D1 via its PTB domains. This interaction
plays an important role in controlling the degree of Ser237 phosphorylation on TBC1D1 and is thus likely to be
important in controlling energy homeostasis in tissues co-expressing α1-containing AMPK heterotrimers and
TBC1D1.
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